Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
22.82
-0.27 (-1.17%)
At close: Jun 13, 2025, 4:00 PM
22.85
+0.03 (0.13%)
After-hours: Jun 13, 2025, 5:05 PM EDT
Genmab Revenue
Genmab had revenue of $715.00M in the quarter ending March 31, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to $3.23B, up 25.43% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.23B
Revenue Growth
+25.43%
P/S Ratio
4.38
Revenue / Employee
$1,204,661
Employees
2,682
Market Cap
14.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GMAB News
- 2 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 4 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 12 days ago - Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Business Wire
- 18 days ago - Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference - GlobeNewsWire
- 23 days ago - Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
- 24 days ago - Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference - GlobeNewsWire
- 25 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 26 days ago - Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology - Seeking Alpha